This report aims to provide analyses of clinical research involving viral and non-viral vectors in gene therapy clinical trials while also identifying trends throughout the years.
Gene therapy is a technique involving the delivery of genetic material into a patient’s cells via vectors to remedy the effects of a defective gene. Over the last decade, the gene therapy field has evolved significantly. Owing to the influx of approvals in recent years, neurodegenerative disorders, genetic diseases, and various cancers previously considered incurable may have a path towards treatment. Pharmaceutical companies are now investing significant resources to harness and fulfill the transformative potential of gene therapy products. However, identifying the most efficient gene delivery mechanism proves to be one of the major obstacles affecting the ability to take full advantage of the capabilities of gene therapies.
Gene therapy is a technique involving the delivery of genetic material into a patient’s cells via vectors to remedy the effects of a defective gene. Over the last decade, the gene therapy field has evolved significantly. Owing to the influx of approvals in recent years, neurodegenerative disorders, genetic diseases, and various cancers previously considered incurable may have a path towards treatment. Pharmaceutical companies are now investing significant resources to harness and fulfill the transformative potential of gene therapy products. However, identifying the most efficient gene delivery mechanism proves to be one of the major obstacles affecting the ability to take full advantage of the capabilities of gene therapies.
Scope
- The clinical trials data used for these analyses were extracted from the publisher's Clinical Trials Database and are segmented in two sections. The first section focuses on gene therapy trends observed in the last 20 years from clinical trials initiated between 2001 to 2021.
- The second portion focuses on clinical research utilizing viral and non-viral gene therapy vectors and includes data from clinical trials initiated from 2011 to 2021. The data have been analyzed by year, phase, status, vector type, therapy area, indication, geography, sponsor type (top industry vs. non-industry sponsors) and reasons for discontinuation. Additional analysis on upcoming approvals, IND filings, and vector type breakdowns have also been included.
Reasons to Buy
- Understand the gene therapy vector landscape
- The trends of gene therapy vector clinical trials
- The trends of viral and non-viral gene therapy vector clinical trials
Table of Contents
- Executive Summary
- Introduction
- Report Scope
- Methodology
- Gene Therapy Trends (2001-2021)
- Analysis of Viral Vectors Involved in Gene Therapy Clinical Trials (2011-2021)
- Analysis of Non-viral Vectors Involved in Gene Therapy Clinical Trials (2011-2021)
- Key Findings
- Appendix
List of TablesTable 1: Viral Vector Gene Therapy Trials Summary (2011-2021)
Table 2: Non-viral Vector Gene Therapy Trials Summary (2011-2021)
List of FiguresFigure 1: Number of Gene Therapy Trials by Year (2001-2021)
Figure 2: Gene Therapy Clinical Trials by Year and Phase (2001-2021)
Figure 3: Gene Therapy Trials by Sponsor Type (2001-2021)
Figure 4: Gene Therapy Trials by Regional Distribution (2001-2021)
Figure 5: Single-Country & Multinational Gene Therapy Trials by Region (2001-2011)
Figure 6: Distribution of Gene Therapy Trials by Top 5 Countries (2001-2021)
Figure 7: Upcoming Regulatory Approvals for Gene Therapy Drugs
Figure 8: Upcoming IND Filings for Gene Therapy Drugs
Figure 9: Number of Clinical Trials by Gene Therapy Vector by Trial Start Year (2011-2021)
Figure 10: Clinical Trials Involving Viral Vector Gene Therapies by Phase and Status (2011-2021)
Figure 11: Clinical Trials Involving Viral Vector Gene Therapies by Trial Start Year and Sponsor Type (2011-2021)
Figure 12: Types of Viral Vectors
Figure 13: Clinical Trials Involving the Top Viral Vector Gene Therapies by Trial Start Year (2011-2021)
Figure 14: Clinical Trials Involving Viral Vector Gene Therapies by Therapy Area (2011-2021)
Figure 15: Clinical Trials Involving Viral Vector Gene Therapies by Indication (2011-2021)
Figure 16: Top Industry Sponsors for Clinical Trials Involving Viral Vector Gene Therapies (2011-2021)
Figure 17: Top Non-industry Sponsors for Clinical Trials Involving Viral Vector Gene Therapies (2011-2021)
Figure 18: Clinical Trials Involving Viral Vector Gene Therapies by Region (2011-2021)
Figure 19: Clinical Trials Involving Viral Vector Gene Therapies by Country (2011-2021)
Figure 20: Clinical Trials Involving Viral Vector Gene Therapies by Country and Year (2011-2021)
Figure 21: Reasons for Trial Discontinuation of Clinical Trials Involving Viral Vector Gene Therapies by Phase (2011-2021)
Figure 22: Reasons for Trial Discontinuation of Clinical Trials Involving Viral Vector Gene Therapies by Sponsor Type (2011-2021)
Figure 23: Clinical Trials Involving Non-viral Vector Gene Therapies by Phase and Status (2011-2021)
Figure 24: Clinical Trials Involving Non-viral Vector Gene Therapies by Trial Start Year and Sponsor Type (2011-2021)
Figure 25: Types of Non-viral Vectors
Figure 26: Clinical Trials Involving Non-viral Vector Gene Therapies by Vector Type and Trial Start Year (2011-2021)
Figure 27: Clinical Trials Involving Non-viral Vector Gene Therapies by Therapy Area (2011-2021)
Figure 28: Clinical Trials Involving Non-viral Vector Gene Therapies by Indication (2011-2021)
Figure 29: Top Industry Sponsors for Clinical Trials Involving Non-viral Vector Gene Therapies (2011-2021)
Figure 30: Top Non-industry Sponsors for Clinical Trials Involving Non-viral Vector Gene Therapies (2011-2021)
Figure 31: Clinical Trials Involving Non-viral Vector Gene Therapies by Region (2011-2021)
Figure 32: Clinical Trials Involving Non-viral Vector Gene Therapies by Country (2011-2021)
Figure 33: Clinical Trials Involving Non-viral Vector Gene Therapies by Country and Year (2011-2021)
Figure 34: Reasons for Trial Discontinuation of Clinical Trials Involving Non-viral Vector Gene Therapies by Phase (2011-2021)
Figure 35: Reasons for Trial Discontinuation of Clinical Trials Involving Non-viral Vector Gene Therapies by Sponsor Type (2011-2021)
